Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
72actual
Sites
68
Countries
Argentina, Brazil, Bulgaria +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor business decision, not related to safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-29 | actual | When the study began enrolling |
| Primary completion | 2025-05-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-08 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Discoid Lupus Erythematosus
Interventions
- Drug: Placebo
- Drug: Daxdilimab — also filed as HZN-7734
Primary outcome
what the primary-completion date above is the date OFMean Change in Cutaneous Lupus Erythematosus Disease and Severity Index-Activity (CLASI-A) Score from Baseline to Week 24
measured Baseline to Week 24
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed